RE:Thoughts on pan can dealFrom PanCan and ONCY's recent joint announcement: "Data presented at SITC 2022 showed a near tripling of overall response rate for pelareorep + gemcitabine + nab-paclitaxel + a PD-L1 inhibitor compared to historical control trials"
PanCan seeks to fund a Phase 3 trial through its network of 20 prestigious clinical trial sites in the United States so that the above quadruple therapy for the treatment of pancreatic cancer can be approved and brought to market quicker than would happen otherwise.
PanCan is seeking to cut through all the "red tape" that otherwise stands in the way of bringing novel and effective drugs to the patient in a timely fashion.
In pancreatic cancer patients do not have time to waste on the traditional clinical trial protocols and this group is intending to accelerate approvals